

Table of Contents

Acknowledgments	iii
Abstract	v
1 Introduction: Big potential for small interfering RNA in cancer therapy	1
1.1 <i>Small interfering RNAs: A new class of cancer therapeutics</i>	1
1.2 <i>Opportunities for siRNA in cancer therapy</i>	2
1.2.1 Targeting chromosomal translocations	2
1.2.2 Reducing the expression of overexpressed or mutated oncogenes	5
1.2.3 Controlling cell survival and death	6
1.3 <i>The challenge of systemic siRNA delivery</i>	7
1.4 <i>An engineering approach for the design of siRNA therapeutics</i>	10
1.5 <i>References</i>	12
2 Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging	15
2.1 <i>Abstract</i>	15
2.2 <i>Introduction</i>	16
2.3 <i>Materials and methods</i>	19
2.3.1 Production of luciferase-expressing cell lines by lentiviral transduction .	19
2.3.2 siRNA duplexes	19
2.3.3 In vitro transfections	20
2.3.4 Formation of subcutaneous tumors in mice	20
2.3.5 Low-pressure tail-vein (LPTV) injection of formulated siRNA nanoparticles	20
2.3.6 High-pressure tail-vein (HPTV) co-injection of plasmid and siRNA	21
2.3.7 Bioluminescent imaging	21
2.3.8 Mathematical model.....	22
2.4 <i>Results</i>	26
2.4.1 Effect of siRNA dose on luciferase knockdown in vitro	27
2.4.2 Effect of cell doubling time on luciferase knockdown in vitro	28
2.4.3 Kinetics of luciferase knockdown by siRNA in subcutaneous tumors	30
2.4.4 Kinetics of luciferase knockdown by siRNA in hepatocytes.....	32
2.4.5 Effect of siRNA stability on luciferase knockdown by siRNA	34
2.4.6 Multiple doses to prolong luciferase knockdown by siRNA in nondividing cells	35
2.4.7 Considerations for siRNA-based treatments that require a threshold knockdown for efficacy.....	37
2.5 <i>Discussion</i>	40

2.6	<i>Acknowledgments</i>	45
2.7	<i>References</i>	46
3	Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing	50
3.1	<i>Abstract</i>	50
3.2	<i>Introduction</i>	51
3.3	<i>Materials and methods</i>	55
3.3.1	Luciferase-expressing cell lines.....	55
3.3.2	siRNA duplexes	55
3.3.3	siRNA serum stability.....	56
3.3.4	In vitro transfection.....	56
3.3.5	Hydrodynamic co-injection of plasmid DNA and siRNA.....	57
3.3.6	Bioluminescent imaging (BLI)	58
3.3.7	Mathematical modeling	58
3.4	<i>Results</i>	59
3.4.1	Verification of luciferase knockdown by multiple siRNA sequences	59
3.4.2	Serum stability of unmodified and nuclease-stabilized siRNAs.....	61
3.4.3	In vitro activity of unmodified and nuclease-stabilized siRNAs in rapidly and slowly dividing cells.....	62
3.4.4	In vivo activity of unmodified and nuclease-stabilized siRNAs after hydrodynamic injection (HDI)	65
3.4.5	Model predictions for the effect of siRNA nuclease stability.....	70
3.5	<i>Discussion</i>	77
3.6	<i>Conclusions</i>	84
3.7	<i>Acknowledgments</i>	85
3.8	<i>References</i>	86
4	Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles	88
4.1	<i>Abstract</i>	88
4.2	<i>Introduction</i>	89
4.3	<i>Materials and methods</i>	93
4.3.1	Formulation of nucleic acid nanoparticles.....	93
4.3.2	Formulation of PEGylated/targeted nucleic acid nanoparticles.....	94
4.3.3	Electrophoretic mobility shift assay.....	95
4.3.4	Individual nanoparticle charge ratio	95
4.3.5	Serum stability	96
4.3.6	Dynamic light scattering (DLS).....	97
4.3.7	Transmission electron microscopy (TEM)	97
4.3.8	Atomic force microscopy (AFM)	97
4.3.9	Isothermal titration calorimetry (ITC)	98

4.3.10	Percentage of AD-PEG ₅₀₀₀ bound after formulation	98
4.3.11	Percentage of AD-PEG ₅₀₀₀ -Tf bound after formulation	99
4.3.12	Multi-angle light scattering (MALS)	100
4.3.13	Individual nanoparticle stoichiometry	100
4.3.14	Salt stability	101
4.3.15	Erythrocyte aggregation.....	101
4.3.16	Complement fixation	102
4.3.17	Cellular uptake.....	103
4.3.18	Competitive uptake	104
4.3.19	Avidity effects.....	104
4.3.20	Luciferase knockdown after siRNA transfection.....	106
4.4	<i>Results and discussion</i>	107
4.4.1	Particle formation requires a slight excess of positive charge and protects siRNA from degradation in serum	107
4.4.2	Formulation conditions affect nanoparticle size and zeta potential.....	109
4.4.3	AD-PEG conjugates bind to the surface of nanoparticles through inclusion complex formation	112
4.4.4	Particle molecular weight can be used to estimate individual nanoparticle stoichiometry.....	115
4.4.5	PEGylation provides steric stabilization to the nanoparticles and reduces nonspecific interactions.....	118
4.4.6	PEGylated nanoparticles show minimal complement fixation.....	121
4.4.7	Particles achieve intracellular delivery of siRNA in vitro	122
4.4.8	Targeting ligands enhance cellular uptake of PEGylated nanoparticles.	124
4.4.9	Targeted nanoparticles exhibit avidity effects	125
4.4.10	Particles deliver functional pDNA and siRNA to cells in vitro.....	127
4.4.11	Nanoparticles are multifunctional, integrated systems for nucleic acid delivery.....	128
4.5	<i>Acknowledgments</i>	129
4.6	<i>References</i>	130
5	Noninvasive in vivo imaging using PET and BLI to monitor the biodistribution and function of tumor-targeted siRNA nanoparticles after intravenous injection in mice.....	132
5.1	<i>Abstract</i>	132
5.2	<i>Introduction</i>	133
5.3	<i>Materials and methods</i>	135
5.3.1	siRNA sequence.....	135
5.3.2	Synthesis of DOTA-siRNA	135
5.3.3	Verification of DOTA-siRNA conjugation	136
5.3.4	In vitro transfection.....	136
5.3.5	⁶⁴ Cu labeling of DOTA-siRNA	137
5.3.6	Nanoparticle formation	137
5.3.7	Dynamic light scattering (DLS).....	138

5.3.8	Serum stability of siRNA nanoparticles	138
5.3.9	Salt stability of siRNA and pDNA nanoparticles	138
5.3.10	Animals and tumor formation	139
5.3.11	MicroPET/CT imaging	139
5.3.12	Bioluminescent imaging (BLI)	140
5.4	<i>Results</i>	141
5.4.1	Synthesis and characterization of DOTA-siRNA	141
5.4.2	Formation of nanoparticles containing DOTA-siRNA	142
5.4.3	⁶⁴ Cu-labeling of DOTA-siRNA	143
5.4.4	Serum stability of DOTA-siRNA nanoparticles	144
5.4.5	Biodistribution of naked siRNA and siRNA nanoparticles after intravenous administration	145
5.4.6	Tumor localization and function of targeted vs. non-targeted siRNA nanoparticles	154
5.5	<i>Discussion</i>	156
5.6	<i>Acknowledgments</i>	161
5.7	<i>References</i>	162

6 Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. 164

6.1	<i>Abstract</i>	164
6.2	<i>Introduction</i>	165
6.3	<i>Materials and methods</i>	167
6.3.1	siRNA sequences	167
6.3.2	In vitro down-regulation of EWS-FLI1 in an EFT cell line	167
6.3.3	Injection of mice with TC71-Luc cells	168
6.3.4	Bioluminescent imaging of the mice	168
6.3.5	Formulation of non-viral, siRNA-containing nanoparticles for in vivo administration	168
6.3.6	Consecutive-day delivery of siRNA to tumors in vivo	169
6.3.7	Real Time Quantitative RT-PCR (Q-RT-PCR)	169
6.3.8	Long-term delivery of siRNA to tumors in vivo	170
6.3.9	Toxicity, immune response, and pathology studies	170
6.4	<i>Results</i>	171
6.4.1	siRNA mediates down-regulation of EWS-FLI1 in cultured TC71 cells	171
6.4.2	Formulated siRNA against EWS-FLI1 inhibits tumor growth in vivo	171
6.4.3	Long-term, twice-weekly administration of targeted, formulated siEFBP2 inhibits tumor cell engraftment	172
6.4.4	No immune response or major organ damage was observed after treatment with targeted nanoparticles	175
6.5	<i>Discussion</i>	177
6.6	<i>Acknowledgments</i>	181

6.7	<i>References</i>	182
7	Growth inhibition of established subcutaneous tumors in mice after intravenous administration of siRNA nanoparticles: Impact of tumor-specific targeting and dosing schedule	184
7.1	<i>Abstract</i>	184
7.2	<i>Introduction</i>	185
7.3	<i>Materials and methods</i>	187
7.3.1	siRNA duplexes	187
7.3.2	In vitro transfection.....	188
7.3.3	Nanoparticle formation.....	189
7.3.4	Dynamic light scattering (DLS).....	189
7.3.5	Animals and tumor formation.....	189
7.3.6	Intravenous administration of siRNA formulations.....	190
7.3.7	Bioluminescent imaging (BLI)	190
7.3.8	Histology and confocal immunofluorescence microscopy	190
7.3.9	Determination of treatment efficacy	191
7.3.10	Tolerability.....	192
7.3.11	Mathematical modeling	192
7.4	<i>Results</i>	193
7.4.1	In vitro growth inhibition by siRNAs targeting RRM2	193
7.4.2	Schedule dependence of tumor growth inhibition in vivo by siRNA nanoparticles	195
7.4.3	Correlation between tumor bioluminescence (BLI) and tumor volume (caliper measurement).....	198
7.4.4	In vivo efficacy of naked siRNA vs. siRNA nanoparticles	200
7.4.5	In vivo efficacy of targeted vs. non-targeted siRNA nanoparticles.....	201
7.4.6	Tumor growth inhibition in vivo correlates with in vitro cell growth inhibition	203
7.4.7	Histology and confocal immunofluorescence microscopy	204
7.4.8	Mathematical model simulations and insights for siRNA-based treatment design	206
7.5	<i>Discussion</i>	210
7.6	<i>Acknowledgments</i>	214
7.7	<i>References</i>	215
8	Future directions	217

Figures

Figure 2.1. Simplified schematic of the key steps required for siRNA delivery to and function within mammalian cells.....	23
Figure 2.2. Effect of siRNA dose on the duration and magnitude of luciferase knockdown by siRNA in nondividing cells.....	28
Figure 2.3. Effect of cell doubling time on the duration of luciferase knockdown by siRNA in vitro.....	30
Figure 2.4. Kinetics of luciferase knockdown by siRNA in Neuro2A-Luc subcutaneous tumors in A/J mice.....	32
Figure 2.5. Kinetics of luciferase knockdown by siRNA in nondividing hepatocytes in BALB/c mice.....	33
Figure 2.6. Effect of intracellular siRNA half-life on the duration of siRNA-mediated gene silencing in vitro.....	35
Figure 2.7. Effect of siRNA dose frequency on the duration of luciferase knockdown by siRNA in nondividing cells.....	36
Figure 2.8. Effect of cell doubling time and target protein half-life on the ability to maintain persistent gene silencing.....	39
Figure 3.1. Validation of luciferase-targeting and control siRNA sequences in rapidly dividing (HeLa) and slowly dividing (CCD) luciferase-expressing cells after Oligofectamine transfection.....	60
Figure 3.2. Nuclease stability of unmodified and nuclease-stabilized siRNAs after incubation at 37°C and 5% CO ₂ in 90% mouse serum.....	62
Figure 3.3. In vitro luciferase knockdown by unmodified and nuclease-stabilized siGL3 in rapidly dividing (HeLa) and slowly dividing (CCD) luciferase-expressing cells after Oligofectamine transfection.....	63
Figure 3.4. In vitro luciferase knockdown by unmodified and nuclease-stabilized siGL3 in HeLa cells after electroporation.....	65
Figure 3.5. Bioluminescent images of BALB/cJ mice after hydrodynamic co-injection of a plasmid containing the firefly luciferase gene under a hepatocyte-specific promoter and unmodified (siCON1, siGL3) or nuclease-stabilized (siCON1stbl, siGL3stbl) siRNAs.....	67
Figure 3.6. Luciferase activity in BALB/cJ mice after hydrodynamic co-injection of a plasmid containing the firefly luciferase gene under a hepatocyte-specific promoter and unmodified or nuclease-stabilized siRNAs.....	68
Figure 3.7. In vivo luciferase knockdown by unmodified and nuclease-stabilized siGL3 in BALB/cJ mice after hydrodynamic co-injection with a plasmid containing the firefly luciferase gene under a hepatocyte-specific promoter.....	70
Figure 3.8. Model predictions for luciferase knockdown in luciferase-expressing cells.	73
Figure 3.9. Model predictions for luciferase knockdown in BALB/cJ mice after HDI...	74
Figure 3.10. Model predictions for the effect of intracellular siRNA degradation rate (<i>k_{deginna}</i>) on luciferase knockdown.....	76
Figure 4.1. Formation of nucleic acid-containing nanoparticles using CDP-Im.....	94
Figure 4.2. Effect of formulation charge ratio (+/-).....	108

Figure 4.3. Nuclease stability of siRNA encapsulated within nanoparticles.....	109
Figure 4.4. Transmission electron microscopy and atomic force microscopy images of unPEGylated and PEGylated siRNA nanoparticles formulated at a charge ratio of 3 (+/-).....	110
Figure 4.5. Effect of nucleic acid concentration ([NA]) during formulation on the size of unPEGylated or PEGylated nanoparticles	111
Figure 4.6. Nanoparticle zeta potential as a function of AD-PEG ₅₀₀₀ -Tf ligand concentration during formulation	112
Figure 4.7. Isothermal titration calorimetry (ITC) plots characterizing binding between AD-PEG ₅₀₀₀ molecules and free CDP-Im or siRNA nanoparticles.....	114
Figure 4.8. Relationship between nanoparticle size and molecular weight (MW) as determined by dynamic and multi-angle light scattering.....	116
Figure 4.9. Aggregation of siRNA nanoparticles in physiological salt solutions.....	119
Figure 4.10. Erythrocyte aggregation	121
Figure 4.11. Complement fixation.....	122
Figure 4.12. Uptake of CDP-Im nanoparticles containing fluorescein (FL)-labeled siRNA by HeLa cells	124
Figure 4.13. Uptake of PEGylated and Tf-targeted nanoparticles in the presence of holo-Tf competitor	125
Figure 4.14. Effect of transferrin targeting ligand density on relative binding affinity. 127	
Figure 4.15. Luciferase expression 48 h after co-transfection of HeLa cells with nanoparticles containing pDNA and siRNA.....	128
Figure 5.1. Luciferase knockdown by unmodified and DOTA-conjugated siRNA in luciferase-expressing Neuro2A-Luc cells.....	142
Figure 5.2. Effective hydrodynamic diameter and zeta potential of nanoparticles formed with 0 to 100% DOTA-siRNA	143
Figure 5.3. Nuclease stability of nanoparticle-encapsulated siRNA after incubation at 37°C and 5% CO ₂ in 50% mouse serum.....	145
Figure 5.4. Fused microPET/CT images of mice at 1, 10, and 60 min after intravenous injection of free ⁶⁴ Cu (Cu), ⁶⁴ Cu-labeled DOTA (DOTA), ⁶⁴ Cu-labeled DOTA-siRNA (Naked), and Tf-targeted nanoparticles (Tf)	146
Figure 5.5. Average time-activity curves for the first 60 min after intravenous injection of ⁶⁴ Cu, ⁶⁴ Cu-labeled DOTA, ⁶⁴ Cu-labeled DOTA-siRNA, and Tf-targeted nanoparticles	148
Figure 5.6. Gel electrophoresis analysis of ⁶⁴ Cu-DOTA-siRNA nanoparticles prior to injection for microPET/CT imaging.....	150
Figure 5.7. Gel electrophoresis analysis of urine samples from mice injected with ⁶⁴ Cu-DOTA-siRNA nanoparticles.....	151
Figure 5.8. NaCl concentration-dependent disruption of Tf-targeted nanoparticles containing unmodified siRNA or pDNA	153
Figure 5.9. Tissue distribution of ⁶⁴ Cu-DOTA-siRNA delivered intravenously by Tf-targeted and non-targeted nanoparticles	154
Figure 5.10. Multimodality in vivo imaging of siRNA nanoparticle delivery and function using microPET/CT and BLI.....	156

Figure 6.1. In vitro knockdown of EWS-FLI1 in cultured TC71 EFT cells.....	171
Figure 6.2. In vivo knockdown of EWS-FLI1 RNA levels in metastasized TC71-Luc tumors in mice.....	172
Figure 6.3. Bioluminescent images of the remaining mice from all treatment groups in NOD/scid mice 3.5 weeks after injection of 5×10^6 TC71-Luc cells.....	174
Figure 6.4. Median tumor size in NOD/scid mice after injection of 5×10^6 TC71-Luc cells on day 0 followed by twice-weekly treatment.....	175
Figure 6.5. Evaluation of toxicity and immune response in mice after a single intravenous administration of formulated siRNA.....	176
Figure 6.6. H&E staining of tissues from mice receiving long-term treatment with 5% glucose, naked siRNA, and Tf-targeted nanoparticles.....	177
Figure 7.1. In vitro growth inhibition of Neuro2A-Luc cells after treatment with siCON, siR2B+6, siR2A+5, and siR2B+5.....	195
Figure 7.2. Effect of siRNA nanoparticle dosing schedule on the in vivo growth inhibition of established subcutaneous Neuro2A-Luc tumors in A/J mice	197
Figure 7.3. Correlation between tumor bioluminescence and tumor volume.....	199
Figure 7.4. Effect of siRNA nanoparticle formulation on the in vivo growth inhibition of subcutaneous Neuro2A-Luc tumors in A/J mice after intravenous injection of naked siRNA or siRNA nanoparticles for three consecutive days	200
Figure 7.5. In vivo growth inhibition of established subcutaneous Neuro2A-Luc tumors in A/J mice after treatment with three independent sequences targeting RRM2 mRNA and an irrelevant control sequence	204
Figure 7.6. H&E staining and confocal immunofluorescence microscopy of Neuro2A-Luc tumor cryosections.....	205
Figure 7.7. Model simulations showing the effect of tumor growth rate on the protein knockdown after siRNA nanoparticle treatment with dosing schedules of 2.5 mg/kg qd \times 1, 2.5 mg/kg q3d \times 3, 2.5 mg/kg qd \times 3, or 5 mg/kg qd \times 3	208
Figure 7.8. Model simulations comparing tumor growth inhibition after siRNA nanoparticle treatment in situations where no new cells are reached or 50% new cells are reached with each additional dose	210

Tables

Table 2.1. Mathematical model variables	23
Table 2.2. Mathematical model parameters	24
Table 4.1. Measured isothermal titration calorimetry (ITC) parameters for the binding between AD-PEG ₅₀₀₀ and β -CD alone, polycation alone (CDP-Im), or CDP- Im/siRNA nanoparticles formulated at charge ratios from 3 to 15 (+/-)	113